Drs Fanning and Richter review the baseline characteristics of patients included in the routine clinical practice publication of ixazomib, lenalidomide, and dexamethasone [IRD] versus lenalidomide and dexamethasone [Rd] in patients with relapsed/refractory multiple myeloma.
Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.
The current rationale for managing a patient with newly diagnosed multiple myeloma with consolidation therapy post-transplant.
Recommendations regarding the appropriate number of cycles of induction therapy before sending a patient with multiple myeloma for stem cell transplantation.
In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.
Reactions to key findings from an article by Birgit Pernthaler, et al, that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer.
GU oncologists discuss toxicities from androgen deprivation therapy and apalutamide as reported in the phase 3 TITAN study.
Multiple myeloma experts share background for discussion of the recent publication, “Survival benefit of ixazomib, lenalidomide and dexamethasone [IRD] over lenalidomide and dexamethasone [Rd] in relapsed and refractory multiple myeloma patients in routine clinical practice.”
In an interview with CancerNetwork® during the 2022 Gastrointestinal Cancer Symposium, Zev A. Wainberg, MD, discussed key updates from the phase 3 KEYNOTE-062 trial, examining pembrolizumab plus or minus chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.
Implications of updated data from the GRIFFIN trial, in terms of using quadruplet therapy to manage patients with newly diagnosed multiple myeloma who are eligible for transplant.
An overview of doublet and triplet regimens used as first-line therapy for patients with newly diagnosed multiple myeloma who are eligible for transplant.
Impressions of the case of a 51-year-old man with newly diagnosed multiple myeloma and considerations that impact candidacy for an autologous stem cell transplant.
Looking forward, Andrzej Jakubowiak, MD, PhD, anticipates CAR T-cell therapy with ciltacabtagene autoleucel will establish its place across various indications for multiple myeloma.
Drs Steven Finkelstein and Louis J. Mazzarelli highlight data revealed in the article “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Birgit Pernthaler, et al.
Yael Cohen, MD, sat down with CancerNetwork® to spotlight a number of promising treatments that are under investigation for patients with heavily-pretreated multiple myeloma.
Multiple myeloma experts share background for discussion of the recent publication, “Survival benefit of ixazomib, lenalidomide and dexamethasone [IRD] over lenalidomide and dexamethasone [Rd] in relapsed and refractory multiple myeloma patients in routine clinical practice.”
Genitourinary oncology experts discuss clinical trials of maintenance therapy for urothelial carcinoma and their clinical impacts.
CancerNetwork®, sat down with Yael Cohen, MD, to discuss the research that lead up to the phase 2 CARTITUDE-2 trial, examining the use of ciltacabtagene autoleucel for those with lenalidomide–refractory multiple myeloma
Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.
Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.
Neeraj Agarwal, MD, and Simon Chowdhury, MD, comment on the secondary end points from the final analysis of the TITAN trial.
Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.
CancerNetwork® spoke with Rafael Fonseca, MD, about findings from a simulation using real-world data sets to compare the utility of daratumumab-containing regimens as either frontline or second-line therapy.
At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about key takeaways learned in the treatment of myelofibrosis during 2021.
In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, dives into response outcomes in different patient subsets of the phase 1/2b CARTITUDE-1 trial of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about clinical trials and treatments being utilized in 2022.
Matthew S. Davids, MD, MMSc, spoke about using venetoclax plus acalabrutinib in the phase 3 MAJIC study for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Drs Agarwal and Chowdhury analyze the survival data from the phase 3 TITAN study of apalutamide in men with mCSPC.
Experts discuss the changing field of advanced urothelial carcinoma and consider sequencing of therapy.
At the 2021 ASH Annual Meeting, Yelena Ginzburg, MD, spoke about presentations she found most groundbreaking.